Clinical Trials Sponsored by Cytokinetics

Total 41 results

Cytokinetics

Recruiting

A Single and Multiple Ascending Dose Study of CK-4021586 in Healthy Adult Participants

Healthy Participants

United States
Cytokinetics

Completed

Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval

Healthy Participants

United States
Cytokinetics

Terminated

A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031) (COURAGE OLE)

Amyotrophic Lateral Sclerosis

Canada, United States, Australia, Spain, Belgium, Ireland, Italy, Netherlands, Sweden
Cytokinetics

Completed

Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure (METEORIC-HF)

Heart Failure With Reduced Ejection Fraction

United States, Hungary, France, Canada, Netherlands, Germany, Poland, Italy, Sweden
Cytokinetics

Completed

Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction (GALACTIC-HF)

Heart Failure

United States, Belgium, Canada, Denmark, France, Italy, Netherlands, United Kingdom, Hungary, Colombia, Mexico, Poland, Russian Federation, Switzerland, Czechia, Turkey, China, Spain, Australia, New Zealand, Chile, Austria, Slovakia, ... and more
Cytokinetics

Completed

COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF)

Chronic Heart Failure | Pharmacokinetics | Left Ventricular Systolic Dysfunction | Left Ventricular Ejection Fraction | Modified Release Oral Formulation | History of Chronic Heart Failure | Echocardiogram

United States, Canada, Italy, Netherlands, United Kingdom, Belgium, Czechia, Australia, Hungary, Poland, Bulgaria, Lithuania, Germany
Cytokinetics

Completed

Pharmacokinetics Study of AMG 423 in Healthy Subjects and Subjects With Various Degrees of Renal Insufficiency

Heart Failure

United States
Cytokinetics

Withdrawn

Omecamtiv Mecarbil Post-trial Access Study

Chronic Heart Failure With Reduced Ejection Fraction
Cytokinetics

Completed

Pharmacokinetics and Safety Study of Omecamtiv Mecarbil in Healthy Japanese Adults

Healthy Volunteer

Japan
Cytokinetics

Completed

A Study of CK-1827452 Infusion in Stable Heart Failure

Heart Failure

United States, United Kingdom, Georgia, Russian Federation
Cytokinetics

Completed

Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

United States, United Kingdom, Germany, Canada, Netherlands, France, Ireland, Spain
Cytokinetics

Completed

Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

United States
Cytokinetics

Completed

A Pharmacokinetic and Pharmacodynamic Study of Omecamtiv Mecarbil in Healthy Volunteers

Heart Failure

United Kingdom
Cytokinetics

Recruiting

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM (ACACIA-HCM)

Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

United States
Cytokinetics

Completed

Dose-finding Study to Evaluate the Safety, Tolerability, PK, and PD of CK-3773274 in Adults With HCM (REDWOOD-HCM)

Hypertrophic Cardiomyopathy (HCM)

United States, Spain, Italy, Netherlands
Cytokinetics

Withdrawn

Pharmacokinetic Study of Omecamtiv Mecarbil in Heart Failure Patients

Heart Failure
Cytokinetics

Completed

Safety, PK, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection Fraction

Heart Failure With Reduced Ejection Fraction

Japan
Cytokinetics

Completed

Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-AHF)

Heart Failure

United States, Canada, Germany, Italy, Netherlands, Belgium, France, Czechia, Australia, Russian Federation, Hungary, Poland, Bulgaria, Slovakia, United Kingdom, Finland, Greece, Lithuania, Norway
Cytokinetics

Completed

A Study for Patients Who Completed VITALITY-ALS (CY 4031) (VIGOR-ALS)

Amyotrophic Lateral Sclerosis (ALS)

United States, Netherlands, Canada, Belgium, United Kingdom, France, Germany, Ireland, Italy, Portugal, Spain
Cytokinetics

Completed

A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects

Healthy Subjects | Symptomatic Obstructive Hypertrophic Cardiomyopathy

United States
Cytokinetics

Completed

A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

United States
Cytokinetics

Completed

PK and Tolerability of IV and Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and Angina

Myocardial Ischemia | Heart Failure | Angina Pectoris

Georgia, Russian Federation
Cytokinetics

Recruiting

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM (MAPLE-HCM)

Obstructive Hypertrophic Cardiomyopathy (oHCM)

United States, Denmark, Spain, Netherlands, United Kingdom, France, China, Israel, Germany, Italy, Hungary, Canada
Cytokinetics

Recruiting

A Single and Multiple Ascending Dose Study of CK-3828136 in Healthy Adult Participants

Healthy Participants

United States
Cytokinetics

Enrolling by invitation

Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM (FOREST-HCM)

Symptomatic Hypertrophic Cardiomyopathy (HCM)

United States, France, Israel, Spain, United Kingdom, Italy, Poland, Hungary, Denmark, Netherlands, Germany, Czechia, Portugal
Cytokinetics

Terminated

A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS) (COURAGE-ALS)

Amyotrophic Lateral Sclerosis

United States, Germany, Spain, Australia, United Kingdom, Canada, France, Belgium, Denmark, Ireland, Italy, Netherlands, Poland, Portugal, Sweden, Switzerland
Cytokinetics

Completed

Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy Adults

QT Intervals Changes | QTc Intervals Changes

United Kingdom
Cytokinetics

Completed

Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year (VITALITY-ALS)

Amyotrophic Lateral Sclerosis

Canada, United States, Netherlands, France, United Kingdom, Belgium, Germany, Spain, Ireland, Italy, Portugal
Cytokinetics

Terminated

Phase II Study of the Effect of CK-1827452 Injection on Myocardial Efficiency

Heart Failure

Canada, United States
Cytokinetics

Completed

A Study of SB-743921 in Non-Hodgkin Lymphoma and Hodgkin Lymphoma

Non-Hodgkin's Lymphoma | Hodgkin's Disease

United States, Russian Federation
Cytokinetics

Completed

A Study of CK-2017357 in Patients With Peripheral Artery Disease and Symptomatic Claudication

Intermittent Claudication | Peripheral Artery Disease

United States
Cytokinetics

Completed

A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

United States
Cytokinetics

Terminated

A Study of Ispinesib in Metastatic Breast Cancer

Breast Neoplasms

Peru
Cytokinetics

Completed

Pharmacokinetics of Oral CK-1827452 in Patients With Stable Heart Failure

Heart Failure

Georgia
Cytokinetics
Astellas Pharma Inc

Completed

A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS) (FORTITUDE-ALS)

Amyotrophic Lateral Sclerosis

United States, Netherlands, Australia, Canada, Ireland, Spain
Cytokinetics
Astellas Pharma Global Development, Inc.

Completed

A Study of CK-2127107 in Patients With Spinal Muscular Atrophy

Spinal Muscular Atrophy

United States, Canada
Cytokinetics
Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.

Completed

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM (SEQUOIA-HCM) (SEQUOIA-HCM)

Obstructive Hypertrophic Cardiomyopathy (oHCM)

United States, France, Spain, Portugal, Germany, China, United Kingdom, Israel, Netherlands, Denmark, Czechia, Hungary, Italy, Poland
Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.
Cytokinetics

Completed

Safety, Tolerability and Pharmacokinetics Study of CK-3773274

Healthy Adult Subjects | Obstructive Hypertrophic Cardiomyopathy

China
Astellas Pharma Global Development, Inc.
Cytokinetics

Completed

A Study to Assess the Effect of CK-2127107 on Physical Function in Subjects With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD)

United States
Astellas Pharma Global Development, Inc.
Cytokinetics

Terminated

A Study to Assess the Anti-fatigability Effect of CK-2127107 in Elderly Male and Female Subjects With Limitations in Mobility

Mobility Limitation

United States
Cytokinetics
National Institute of Neurological Disorders and Stroke (NINDS)

Terminated

Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis

Myasthenia Gravis

United States

Clinical Trials Sponsored by Cytokinetics

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations